MARKET

OTIC

OTIC

Otonomy
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.060
0.000
0.00%
Closed 16:00 03/27 EDT
OPEN
2.000
PREV CLOSE
2.060
HIGH
2.110
LOW
1.995
VOLUME
106.38K
TURNOVER
--
52 WEEK HIGH
4.180
52 WEEK LOW
1.530
MARKET CAP
63.48M
P/E (TTM)
-1.4164
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of OTIC and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average OTIC stock price target is 7.60 with a high estimate of 10.00 and a low estimate of 3.000.

EPS

OTIC News

More
  • Edited Transcript of OTIC earnings conference call or presentation 27-Feb-20 9:30pm GMT
  • Thomson Reuters StreetEvents · 1d ago
  • The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
  • Benzinga · 03/17 15:38
  • Stocks To Watch: 0% To The Rescue?
  • Seeking Alpha - Article · 03/14 12:49
  • Easy Come, Easy Go: How Otonomy (NASDAQ:OTIC) Shareholders Got Unlucky And Saw 91% Of Their Cash Evaporate
  • Simply Wall St. · 03/09 20:53

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About OTIC

Otonomy, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics for diseases and disorders of the ear. The Company's product candidates include OTIPRIO, OTO-104 and OTO-311. OTIPRIO is a single-dose, physician-administered antibacterial, which is used for the treatment of pediatric patients with bilateral otitis media with effusion undergoing tympanostomy tube placement (TTP) surgery and is available for commercial purchase. OTO-104 is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Meniere's disease and other inner ear conditions. OTO-311 is a sustained-exposure formulation of the N-Methyl-D-Aspartate (NMDA) receptor antagonist gacyclidine in development for the treatment of tinnitus. It also has various other product candidates, which target sensorinerual hearing loss, including age-related hearing loss, also known as presbycusis.
More

Webull offers kinds of Otonomy Inc stock information, including NASDAQ:OTIC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, OTIC stock news, and many more online research tools to help you make informed decisions.